Kidney graft

Cugini D, Azzollini N, Gagliardini E, et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005 67 1753-1761. 

Busnach, G. et al., Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients A randomized placebo-controlled study, J Nephrol, 11, 87, 1998. 

Phase Ilb (prevention of tile rejection of kidney graft)... 

Organ transplants The safety and efficacy of peginterferon alfa-2b alone or in combination with ribavirin capsules for the treatment of hepatitis C in patients who have received liver or other organ transplants have not been studied. Preliminary data indicate that interferon alpha therapy may be associated with an increased rate of kidney graft rejection. Liver graft rejection also has been reported, but a causal... 

Voclosporin (ISA-247, R1524) 88 (Isotechnika) is being evaluated in a Phase III trial for the treatment of psoriasis,250 as well as a Phase III trial by Lux Biosciences as for the treatment of uveitis (coded as LX211, Luveniq ).251,252 In addition, voclosporin 88 has completed a Phase lib trial for the prevention of kidney graft rejection. Voclosporin 88253,254 is a slightly more potent but less toxic semi-synthetic derivative of the fungal-derived immunosuppressant cyclosporin A 89, which has the same mechanism of calcineurin inhibition. Cyclosporin A 89 was first isolated from Tolypocladium inflatum by workers at Sandoz and its structure was published in 1976.255,256... 

Tacrolimus is a macrolide immunosuppressant agent that is isolated from a bacterium. It acts like ciclosporin and is used to protect and treat liver and kidney grafts when conventional immunosuppressants fail. Such rescue treatment may be graft-or life-saving. Tacrolimus may cause nephrotoxicity, neurotoxicity, disturbance of glucose metabolism, hyperkalaemia and hypertrophic cardiomyopathy. 

Ramsey G, Israel L, Lindsay GD, Mayer TK, Nusbacher J. Anti-Rho(D) in two Rh-positive patients receiving kidney grafts from an Rh-immunized donor. Transplantation 1986 41(l) 67-9. 

Bren AF, Kandus A, Buturovic J, Koselj M, Kaplan Pavlovcic S, Ponikvar R, Kovac D, Lindic J, Vizjak A, Ferluga D. Cyclosporine-related hemolytic-uremic syndrome in kidney graft recipients clinical and histomorpho-logic evaluation. Transplant Proc 1998 30(4) 1201-3. 

Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP. Effect of long-term inununosuppression in kidney-graft recipients on cancer incidence randomised comparison of two cyclosporin regimens. Lancet 1998 351(9103) 623-8. 

Olbricht C, Wanner C, Eisenhauer T, Khem V, Doll R, Boddaert M, O Grady P, Krekler M, Mangold B, Christians U. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Chn Pharmacol Ther 1997 62(3) 311-21. 

Conclusions have differed as to whether use of etherified starch in brain-dead organ donors influences kidney graft function at 1, 3, and 6 months after transplantation (30-32). In one report (33), during the first 10 days after transplantation there was reduced kidney graft function... 

Leflunomide has been used as an immunosuppressive agent in kidney and liver transplant recipients to spare cal-cineurin inhibitors and glucocorticoids and to slow progression of chronic kidney graft dysfunction (28,37) (Table 1). 

Eberhard OK, Kliem V, Brunkhorst R. Five cases of Kaposi s sarcoma in kidney graft recipients possible influence of the immunosuppressive therapy. Transplantation 1999 67(l) 180-4. 

Opelz G. Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. Transplant Proc 1999 31 1147-1148. 

Maestri M, Dafoe DC, Adams GA,Gaspari A, Luzzana F, Innocente F, Rademacher J, Dionigi P, Barbieri A, Zonta F,Zonta A, Rabkin R. Insulin-like growth factor-1 ameliorates delayed kidney graft function and the acute nephrotoxic effects ofcyclosporine. Transplantation 1997 64 185-190. 

Bren A, Pajek J, Grego K, Buturovic J, Ponikvar R, Lindic J, Knap B, Vizjak A, Ferluga D, Kandus A. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.Transplant Proc 2005 37 1889-1891. 

Stallone G, Di Paolo S, Schena A, Infante B, Grandaliano G, Battaglia M, Gesualdo L, Schena FP. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.Transplantation 2003 75 998-1003. 

Pinheiro El, Camara N, Osaki K, De Moura E, Pacheco-Silva A. Early presence of calcium oxalate deposition In kidney graft biopsies Is associated with poor long-term graft survival. Am.J.Transplantatlon 2005 5 323-9. 

K.-F. Sewing, Sensitive and specific quantification of sirolimus and its metabolites in blood of kidney graft recipients by LC-ESI-MS, Clin. Chem., 42 (1996) 1417. 

Zhong XY, Hahn D, Troeger C, Klemm A, Stein G, Thomson P, et al. Cell-free DNA in urine a marker for kidney graft rejection, but not for prenatal diagnosis Ann N Y Acad Sd 2001 945 250-7. 

Gjertson DW, Cecka JM, Terasaki PL The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995 60 1384-8. 

Bittar, A.E. Keitel, E. Garcia, C.D. Bruno, R.M. Silviera, A.E. Messias, A. Garcia, V.D. Patient noncoin-pliance as a cause of late kidney graft failure. Transplant. Proc. 1992, 24, 2720-2721. 

Fig. 5. A nonlinear map (NLM) of 33 human urine samples from patients after kidney transplantation based on the levels of six urinary metabolic descriptors. The diamonds correspond to patients showing good kidney graft function after transplantation, the squares are from patients showing cyclosporin nephrotoxicity and the circles are from patients with kidney rejection.

Corticosteroids, CSA, TAC, and impaired kidney graft function may cause post-transplant hypertension. The primary mechanism of CI-associated hypertension in heart transplant recipients may be related to the Cl-induced stimulation of intact renal sympathetic nerves and the absence of reflex cardiac inhibition of the sympathetic nervous system, but a number of other mechanisms, including decreased prostacyclin and nitric oxide production, also have been proposed. " In addition to the propensity to cause peripheral vasoconstriction, CIs promote sodium retention, resulting in extracellular fluid volume expansion. TAC appears to have less potential to induce hypertension following transplantation than CSA. Most classes of antihypertensive medications effectively reduce blood pressure in transplant patients (see Chap. 13). ... 

We analyzed tubular function in developing human kidney grafts established in immunodeficient mice, with Te-DMSA renography, the uptake of which occurs through the peritubular side [29]. Positive uptake of the radioisotope was demonstrated only in tubules that matured in developed grafts. To further determine kidney functionality, we measured levels of urea nitrogen and creatinine in cyst fluid collected from cysts arising from trans-... 

Sariola H, Ekblom P, Lehtonen E, Saxen L. Differentiation and vascularization of the me-tanephric kidney grafted on the chorioallantoic membrane. Dev. Biol. 1983 96 427-435. 

Transient kidney graft dysfunction and acute tubular necrosis... 

Increased expression of adhesion molecules on the kidney graft. 

Goldman, M., J.L. Van Laethem, D. Abramowicz, L. De Pauw, P. Kinnaert and P. Vereerstraeten. Evolution of renal function during treatment of kidney graft rejection with OKT3 monoclonal antibody. Transplantation 1990 50(1) 158-159. 

Opelz, G. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation 40, 240-243 (1985). 

---